Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la Base de données des annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
NabumetoneF1 I SEP / 98
Nadolol and its saltsF1 I SEP / 98
Nadroparin and its saltsF1 I SEP / 99
Nafarelin and its salts and derivativesF1 I SEP / 98
Nalbuphine and any salt thereofC2 I JUN / 02
Nalidixic acidF1 I SEP / 98
Nalmefene and its saltsF1 I SEP / 99
NalorphineN I JUN / 02
Naloxegol or its saltsPDL

including but not limited to naloxegol oxalate

I JUN / 15
Naloxone hydrochloride injection,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone hydrochloride nasal spray,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone or its saltsPDL

including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose

I FEB / 17
Naltrexone and its salts and derivativesF1 I OCT / 09
NandroloneC3 I JUN / 02
Naphazoline and its salts in nasal preparations for pediatric use II SEP / 98
Naphazoline and its salts. in nasal preparations for adult use and in ophthalmic products U
Naproxen or its saltsPDL

except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base)

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

I MAR / 15
Naproxen or its salts..

in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

U MAR / 15
Naproxen or its salts..

in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

III MAR / 15
Naratriptan and its saltsF1 I SEP / 99
Narcotine and its salts Noscapine III SEP / 98
NatalizumabF1 I APR / 08
Nateglinide and its salts and derivativesF1 I OCT / 03
NecitumumabPDL I APR / 17
Nedocromil and its saltsF1 I SEP / 98
Nefazodone and its saltsF1 I SEP / 98
NelarabineF1 I MAY / 10
Nelfinavir and its saltsF1 I SEP / 99
Neocinchophen and its saltsF1 I SEP / 98
Neomycin and its salts and derivativesF2 I SEP / 98
Neostigmine saltsF1 I SEP / 98
NepafenacF1 I OCT / 09
Nesiritide or its saltsPDL I DEC / 13
Netilmicin and its salts and derivativesF1 I SEP / 98
NetupitantPDL I DEC / 17
Nevirapine and its saltsF1 I MAY / 00
Niacin in extended-release formulations nicotinic acid II DEC / 98
Niacin. in immediate-release formulations U DEC / 98
Niacinamide for topical use U OCT / 98
Niacinamide. oral U OCT / 98
Nialamide and its saltsF1 I SEP / 98
NicarbazinF2 I SEP / 98
Nicardipine and its saltsF1 I SEP / 98
NicocodineN I JUN / 02
NicomorphineN I JUN / 02
Nicotine and its salts, for human useF1

(except: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit. )

I JUN / 06
Nicotine and its salts.

when sold as a chewing gum containing not more than the equivalent of 4 mg of nicotine per dosage unit

U NOV / 00
Nicotine and its salts..

when sold as a transdermal patch with a delivery rate of not more than the equivalent of 22 mg

U NOV / 00
Nicotine and its salts...

when sold in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit

U JAN / 05
Nicotine and its salts....

when sold in the form of a lozenge containing 4 mg or less of nicotine per dosage unit

U JUN / 06
Nicotinic acidF1 When sold in (a) a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 mg per dosage unit or per daily dose I JUN / 08
Nicotinyl-tartrate I SEP / 98
NifedipineF1 I SEP / 98
Nikethamide I SEP / 98
Nilotinib and its saltsF1 I MAY / 10
NilutamideF1 I SEP / 98
NimetazepamTS I JUN / 02
Nimodipine and its saltsF1 I SEP / 98
Nintedanib or its saltsPDL I AUG / 15
NitisinonePDL I NOV / 16
Nitrazepam and its saltsTS I SEP / 98
Nitric oxideF1 I FEB / 07
Nitrofurantoin and its saltsF2 I SEP / 98
Nitroglycerin except for sublingual immediate release dosage forms I SEP / 98
Nitroglycerin. sublingual immediate release dosage forms II SEP / 98
NitroscanateF1 I MAY / 00
NivolumabPDL I JAN / 16
Nizatidine and its saltsF1 except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine I SEP / 98
Nizatidine and its salts when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine* I SEP / 98
Nomifensine and its saltsF1 I SEP / 98
NoracymethdolN I JUN / 02
NorboletoneC3 I JUN / 02
NorclostebolC3 I JUN / 02
NorcodeineN I JUN / 02
NordazepamTS I JUN / 02
Norepinephrine and its salts levarterenol, noradrenaline II SEP / 98
NorethandroloneC3 I JUN / 02
NorfloxacinF1 I SEP / 98
NorlevorphanolN I JUN / 02
NormethadoneN I JUN / 02
NormorphineN I JUN / 02
NorpethidineN I JUN / 02
NorpipanoneN I JUN / 02
Nortriptyline and its saltsF1 I SEP / 98
Noscapine III SEP / 98
Novobiocin and its salts and derivativesF2 I SEP / 98
NusinersenPDL I AUG / 17
Nylidrin and its saltsF1 I SEP / 98
Nystatin and its salts and derivativesF2 except preparations for topical use on the skin I SEP / 98
Nystatin and its salts and derivatives. in topical preparations for use on the skin III SEP / 98

90 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled